Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model

Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model

Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-kDa glycoprotein, has demonstrated anti-vasopermeability properties. In this study, we demonstrated that the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphil...

Full description

Bibliographic Details
Main Authors: Ching-Hsein Chen, Chia-Hui Hung, Miao-Fen Chen, Chien-Hsiung Lai, Lin-Cheng Yang, Li-Ju Lai, Chung-Yi Chen, San-Ni Chen, Chien-Neng Kuo
Format: Article
Language:English
Published: MDPI AG 2013-04-01
Series:International Journal of Molecular Sciences
Subjects:
bevacizumab
PEDF
VEGF
bFGF
cornea
angiogenesis
SAINT-18
Online Access:http://www.mdpi.com/1422-0067/14/4/8291

Internet

http://www.mdpi.com/1422-0067/14/4/8291

Similar Items